Intralesional BO-112 Surfaces as Nonsurgical Option for High-Risk BCC
Intralesional BO-112, a TLR3/MDA5-agonist double-stranded RNA complex, shows early promise as a nonsurgical approach for high-risk basal cell carcinoma, Dermatology Times reports.
Topic
Bo 112
Topic
Bo 112
Intralesional BO-112 Emerges as Nonsurgical Option for High-Risk BCC
Intralesional BO-112, a TLR agonist, shows early promise as a nonsurgical treatment for high-risk basal cell carcinoma, Dermatolo…
Highlight Therapeutics Reports Positive Phase 2b Data for Intralesional BO-112 in Basal Cell Carcinoma
Positive Phase 2b topline results for intralesional BO-112 in localized basal cell carcinoma were presented as a late-breaker at…
BO-112 Hits Primary Endpoint in Phase 2b Basal Cell Carcinoma Trial
Phase 2b Spotlight-204 data presented at EADV show intralesional BO-112 produced visual and pathological response in 61% of BCC p…